Autolus Therapeutics PLC (AUTL)
3.01
-0.28
(-8.51%)
USD |
NASDAQ |
Nov 14, 16:00
3.02
+0.01
(+0.33%)
After-Hours: 20:00
Autolus Therapeutics Research and Development Expense (Quarterly): 36.61M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 36.61M |
| March 31, 2024 | 30.67M |
| December 31, 2023 | 25.16M |
| September 30, 2023 | 37.24M |
| June 30, 2023 | 33.23M |
| March 31, 2023 | 27.39M |
| December 31, 2022 | 7.548M |
| September 30, 2022 | 37.63M |
| June 30, 2022 | 38.21M |
| March 31, 2022 | 33.96M |
| December 31, 2021 | 15.68M |
| Date | Value |
|---|---|
| September 30, 2021 | 32.29M |
| June 30, 2021 | 32.13M |
| March 31, 2021 | 30.73M |
| December 31, 2020 | 38.73M |
| September 30, 2020 | 33.54M |
| June 30, 2020 | 31.33M |
| March 31, 2020 | 31.29M |
| December 31, 2019 | 29.37M |
| September 30, 2019 | 27.31M |
| June 30, 2019 | 26.17M |
| March 31, 2019 | 22.56M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
7.548M
Minimum
Dec 2022
38.73M
Maximum
Dec 2020
30.67M
Average
32.13M
Median
Jun 2021
Research and Development Expense (Quarterly) Benchmarks
| Adaptimmune Therapeutics PLC | 40.45M |
| Biodexa Pharmaceuticals PLC | -- |
| NuCana PLC | 8.540M |
| TC BioPharm (Holdings) PLC | 1.648M |
| Verona Pharma PLC | 10.55M |